Advertisement

Biotherapy

, Volume 4, Issue 1, pp 23–30 | Cite as

Spontaneous regression of cancer: New insights

  • Basil A. Stoll
Article

Abstract

Suppression of oncogene expression and of host- or tumour-expressed growth factors and receptors may precipitate spontaneous regression or dormancy in human cancer. Loss of oncogenes necessary for progressive proliferation can lead to differentiation changes. Both natural factors and chemical agents can trigger such a change, and of the naturally occurring agents, growth factors and immunological factors have been most studied. We may find new clues to biological methods of prolonging arrest of cancer, by looking for cytogenetic abnormalities, alterations in oncogene expression and immunocytological composition, in patients showing prolonged dormancy of cancer.

Key words

cancer dormancy spontaneous regression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Everson TC, Cole WH. Spontaneous regression of cancer. Philadelphia: W.B. Saunders, 1966.Google Scholar
  2. 2.
    Boyd, W. The spontaneous regression of cancer. Springfield, Illinois: Charles C. Thomas, 1966.Google Scholar
  3. 3.
    Stephenson HE, Delmez JA, Renden DI, Kimpton RS et al. Host immunity and spontaneous regression of cancer; computerized data reduction study. Surg Gynec Obst 1971; 133: 649–55.Google Scholar
  4. 4.
    Baker HW. Biological control of cancer; the James Ewing Lecture. Arch Surg 1986; 121: 1237–41.PubMedGoogle Scholar
  5. 5.
    Brown GE. New concepts in tumour cell dormancy. Rev Endoc Related Cancer 1989; 32: 23–8.Google Scholar
  6. 6.
    Eccles SA, Alexander P. Immunologically mediated restraint of latent tumour metastases. Nature 1975; 257: 52–3.PubMedGoogle Scholar
  7. 7.
    Noble RL, Hoover L. A classification of transplantable tumors in Nb rats controlled by estrogen from dormancy to autonomy. Cancer Res 1975; 35: 2935–8.PubMedGoogle Scholar
  8. 8.
    Parkinson DR. Interleukin 2; further progress through greater understanding. J Nat Cancer Inst 1990; 82: 1374–6.PubMedGoogle Scholar
  9. 9.
    Rosenberg SA, Latze MT, Aebersold PM et al. Experience with the use of high dose interleukin 2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–85.PubMedGoogle Scholar
  10. 10.
    Stoll BA. Prolonged survival in breast cancer. In: Stoll BA, ed. Prolonged arrest of cancer. Chichester: John Wiley, 1982: 59–86.Google Scholar
  11. 11.
    Rees GJG. Abscopal regression following radiotherapy for adenocarcinoma. Brit J Radiol 1983; 56: 63–6.PubMedGoogle Scholar
  12. 12.
    Roberts AR, Sporn MB. Growth factors related to transformation. In: Harris JR et al., eds. Breast diseases. New York: Lippincott, 1987: 67–80.Google Scholar
  13. 13.
    Kinnon C, Levinsky RJ. Gene therapy for cancer. Eur J Cancer 1990; 26: 638–40.PubMedGoogle Scholar
  14. 14.
    Carlsen NLT. How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br J Cancer 1990; 61: 441–6.PubMedGoogle Scholar
  15. 15.
    Haas D, Ablin AR, Miller C et al. Complete pathologic maturation and regression of Stage 4S neuroblastoma without treatment. Cancer 1988; 62: 818.PubMedGoogle Scholar
  16. 16.
    Thiele CJ, Reynolds CP, Israel MJ. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985; 313: 404–6.PubMedGoogle Scholar
  17. 17.
    Sporn MB, Roberts AB. Transforming growth factor beta. J Am Med Assoc 1989; 262: 938–41.Google Scholar
  18. 18.
    Bookstein P, Shew JY, Chen PL et al. Suppression of tumourigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 1990; 247: 712–5.PubMedGoogle Scholar
  19. 19.
    Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. J Urol 1977; 118: 538–46.PubMedGoogle Scholar
  20. 20.
    Sroujieh AS. Spontaneous regression of intestinal malignant melanoma from an occult primary site. Cancer 1988; 62: 1247–50.PubMedGoogle Scholar
  21. 21.
    Franklin CIV. Spontaneous regression of metastases from testicular tumours; a report of six cases from one centre. Clin Radiol 1977; 28: 499–502.PubMedGoogle Scholar
  22. 22.
    Poppema S, Postma L, Brinker M, de Jong B. Spontaneous regression of a small non-cleaved cell malignant lymphoma. Cancer 1988; 62: 791–4.PubMedGoogle Scholar
  23. 23.
    Coley NH, Fowler GA, Bogatho FH. A review of the influence of bacterial infections and of bacterial products (Coley's toxins) on malignant tumors in man. Acta Med Scand (Suppl) 1953; 274: 29–97.Google Scholar
  24. 24.
    Carswell EA, Old LJ, Kassel RJ et al. An endotoxin induced serum factor that causes necrosis of tumors. Proc Nat Acad Sci USA 1975; 72: 3666–70.PubMedGoogle Scholar
  25. 25.
    Balkwill FR, Naylor MS, Malik S. Tumour necrosis factor as an anticancer agent. Eur J Cancer 1990; 26: 641–4.PubMedGoogle Scholar
  26. 26.
    Saracco S, Abramowsky C, Taylor S, Silverman RA, Berman BW. Spontaneously regressing adrenocortical carcinoma in a newborn. Cancer 1988; 62: 507–11.PubMedGoogle Scholar
  27. 27.
    Tisdale MJ. Scope and limitations of antimitotic therapy. In: Stoll BA, ed. Prolonged arrest of cancer. Chichester: John Wiley, 1982: 407–18.Google Scholar
  28. 28.
    Campisi J, Gray HE, Pardee AB aet al. Cell cycle control of c myc but not c ras is lost following chemical transformation. Cell 1984; 36: 241–7.PubMedGoogle Scholar
  29. 29.
    Hong WK, Wittes RE, Hajdu ST et al. The evolution of mature teratoma from malignant testicular tumors. Cancer 1977; 40: 2987–92.PubMedGoogle Scholar
  30. 30.
    Friedman SJ, Skehan P. Morphological differentiation of human choriocarcinoma cells induced by methotrexate. Cancer Res 1979; 39: 1960–7.PubMedGoogle Scholar
  31. 31.
    Buesow SC, Gillespie GY. Interferon alpha and gamma promote myeloid differentiation of HL60, a human acute promelocytic cell line. J Biol Resp Mod 1984; 3: 653–62.Google Scholar
  32. 32.
    Niederle N, Kloke O, Osieka R et al. Interferon alpha 26 in the treatment of chronic myelogenous leukemia. Sem Oncol 1987; 14 (Suppl 2): 29–36.Google Scholar
  33. 33.
    Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promeeoocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577–80.PubMedGoogle Scholar
  34. 34.
    Bollag W. Retinoids and cancer. Cancer Chemother Pharmacol 1979; 3: 207–15.PubMedGoogle Scholar
  35. 35.
    Lewison EF Spontaneous regression of breast cancer. Nat Cancer Inst Monog 1976; 44: 23–9.Google Scholar
  36. 36.
    Krutchik AN, Buzdar AU, Blumenschein GR, Lukeman JM. Spontaneous regression of breast carcinoma. Arch Int Med 1978; 138: 1734–5.Google Scholar
  37. 37.
    Wheelock EF, Brodovsky HS. Dormant cancer. In: Stoll BA, ed. Prolonged arrest of cancer. Chichester: John Wiley, 1982: 87–102.Google Scholar
  38. 38.
    Lippman ME, Allegra JC. Quantitative estrogen receptor analysis; response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease free-interval. Cancer 1980; 46: 2829–34.PubMedGoogle Scholar
  39. 39.
    Perez R, Pascual M, Macias A, Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat 1984; 4: 189–93.PubMedGoogle Scholar
  40. 40.
    Bates SE, Davidson NE, Valverius EM et al. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer; its regulation by estrogen and its possible functional significance. Mol Endoc 1988; 2: 543–55.PubMedGoogle Scholar
  41. 41.
    Lippman ME, Dickson RB, Bates S et al. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 1986; 75: 59–70.Google Scholar
  42. 42.
    Ikemi Y, Nagakawa S, Nagakawa T, Sugita M. Quoted by Fox BH. Journal Behav Med 1978; 1: 45–9.Google Scholar
  43. 43.
    Cole WH. Spontaneous regression of cancer; the metabolic triumph of the host. Ann NY Acad Sci 1974; 230: 111–41.PubMedGoogle Scholar
  44. 44.
    Sindelar WF, Ketchman AS. Regression of cancer following surgery. Nat Cancer Inst Monog 1976; 44: 81–4.Google Scholar
  45. 45.
    Fox BH, Newberry BH. Impact of psychoendocrine systems in cancer and immunity. New York: C.J. Hogrefe, 1984.Google Scholar
  46. 46.
    Ader R. Psychoneuroimmunology. New York: Academic Press, 1981.Google Scholar
  47. 47.
    Levy S, Herberman R, Lippman M, D'Angelo I. Correlation of stress factors with sustained depression of NK cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol 1987; 5: 348–53.PubMedGoogle Scholar
  48. 48.
    Le Goaster J, Le Magnen J. Neurobiology and cancer; possible role of beta endorphins in cancer growth regulation 1987; 1: 204–7.Google Scholar
  49. 49.
    Faguet GB, Davis HC. Survival in Hodgkins Disease; the role immunocompence and other major risk factors. Blood 1982; 59: 938–45.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Basil A. Stoll
    • 1
  1. 1.Department of OncologySt. Thomas' HospitalLondonUK

Personalised recommendations